Elzorkany K, Kora MAE, Wahed ASA, et al. - In view of the uncertainty concerning the effect of direct acting antiviral agents (DAAs) on renal function in postliver transplant hepatitis C virus (HCV)-positive patients, especially accounting the possibility of drug interactions between immunosuppressants and DAAs, researchers conducted a retrospective observational study including 84 postliver transplant patients with HCV infection. They divided the patients into two groups: group I was administered sofosbuvir plus ribavirin for 24 weeks, group II was administered sofosbuvir plus daclatasvir for 12 weeks. Per findings, postliver transplant patients with HCV infection well tolerated DDAs. These patients had stable renal function in correlation with receiving DDAs. In addition, relatively better renal safety was reported in correlation with providing sofosbuvir plus daclatasvir regimen vs sofosbuvir plus ribavirin.